Reduction of GAG storage in MPS II mouse model following implantation on encapsulated recombinant myoblasts

Adelaide Friso, Rosella Tomanin, Sabrina Alba, Nicoletta Gasparotto, Elisabetta Piller Puicher, Mariella Fusco, Gonzalo Hortelano, Joseph Muenzer, Oriano Marin, Franco Zacchello, Maurizio Scarpa

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: Hunter syndrome, mucopolysaccharidosis type II (MPS II), is a X-linked inherited disorder caused by the deficiency of the enzyme iduronate-2-sulfatase (IDS), involved in the lysosomal catabolism of the glycosaminoglycans (GAG) dermatan and heparan sulfate. Such a deficiency leads to the intracellular accumulation of undegraded GAG and eventually to a progressive severe clinical pattern. Many attempts have been made in the last two to three decades to identify possible therapeutic strategies for the disorder, including gene therapy and somatic cell therapy. Methods: In this study we evaluated the intraperitoneal implantation of allogeneic myoblasts over-expressing IDS, enclosed in alginate microcapsules, in the MPS II mouse model. Animals were monitored for 8 weeks post-implantation, during which plasma and tissue IDS levels, as well as tissue and urinary GAG contents, were measured. Results and conclusions: induced enzyme activity occurred both in the plasma and in the different tissues analyzed. A significant decrease in urinary undegraded GAG between the fourth and the sixth week of treatment was observed. Moreover, a biochemical reduction of GAG deposits was measured 8 weeks after treatment in the liver and kidney, on average 30 and 38%, respectively, while in the spleen GAG levels were almost normalized. Finally, the therapeutic effect was confirmed by histolochemical examination of the same tissues. Such effects were obtained following implantation of about 1.5 × 106 recombinant cells/animal. Taken together, these results represent a clear evidence of the therapeutic efficacy of this strategy in the MPS II mouse model, and encourage further evaluation of this approach for potential treatment of human beings.

Original languageEnglish
Pages (from-to)1482-1491
Number of pages10
JournalJournal of Gene Medicine
Volume7
Issue number11
DOIs
Publication statusPublished - Nov 2005
Externally publishedYes

Fingerprint

Mucopolysaccharidosis II
Myoblasts
Glycosaminoglycans
Iduronate Sulfatase
Mucopolysaccharidosis I
Therapeutics
Dermatan Sulfate
Heparitin Sulfate
Therapeutic Uses
Enzymes
Cell- and Tissue-Based Therapy
Genetic Therapy
Capsules
Spleen
Kidney
Liver

Keywords

  • Gene therapy
  • Hunter syndrome
  • Lysosomal enzymes
  • Microcapsules
  • MPS II mouse model
  • Somatic cell therapy

ASJC Scopus subject areas

  • Genetics

Cite this

Friso, A., Tomanin, R., Alba, S., Gasparotto, N., Puicher, E. P., Fusco, M., ... Scarpa, M. (2005). Reduction of GAG storage in MPS II mouse model following implantation on encapsulated recombinant myoblasts. Journal of Gene Medicine, 7(11), 1482-1491. https://doi.org/10.1002/jgm.790

Reduction of GAG storage in MPS II mouse model following implantation on encapsulated recombinant myoblasts. / Friso, Adelaide; Tomanin, Rosella; Alba, Sabrina; Gasparotto, Nicoletta; Puicher, Elisabetta Piller; Fusco, Mariella; Hortelano, Gonzalo; Muenzer, Joseph; Marin, Oriano; Zacchello, Franco; Scarpa, Maurizio.

In: Journal of Gene Medicine, Vol. 7, No. 11, 11.2005, p. 1482-1491.

Research output: Contribution to journalArticle

Friso, A, Tomanin, R, Alba, S, Gasparotto, N, Puicher, EP, Fusco, M, Hortelano, G, Muenzer, J, Marin, O, Zacchello, F & Scarpa, M 2005, 'Reduction of GAG storage in MPS II mouse model following implantation on encapsulated recombinant myoblasts', Journal of Gene Medicine, vol. 7, no. 11, pp. 1482-1491. https://doi.org/10.1002/jgm.790
Friso, Adelaide ; Tomanin, Rosella ; Alba, Sabrina ; Gasparotto, Nicoletta ; Puicher, Elisabetta Piller ; Fusco, Mariella ; Hortelano, Gonzalo ; Muenzer, Joseph ; Marin, Oriano ; Zacchello, Franco ; Scarpa, Maurizio. / Reduction of GAG storage in MPS II mouse model following implantation on encapsulated recombinant myoblasts. In: Journal of Gene Medicine. 2005 ; Vol. 7, No. 11. pp. 1482-1491.
@article{2d9301d90f1f4270b7c5a322de091ce9,
title = "Reduction of GAG storage in MPS II mouse model following implantation on encapsulated recombinant myoblasts",
abstract = "Background: Hunter syndrome, mucopolysaccharidosis type II (MPS II), is a X-linked inherited disorder caused by the deficiency of the enzyme iduronate-2-sulfatase (IDS), involved in the lysosomal catabolism of the glycosaminoglycans (GAG) dermatan and heparan sulfate. Such a deficiency leads to the intracellular accumulation of undegraded GAG and eventually to a progressive severe clinical pattern. Many attempts have been made in the last two to three decades to identify possible therapeutic strategies for the disorder, including gene therapy and somatic cell therapy. Methods: In this study we evaluated the intraperitoneal implantation of allogeneic myoblasts over-expressing IDS, enclosed in alginate microcapsules, in the MPS II mouse model. Animals were monitored for 8 weeks post-implantation, during which plasma and tissue IDS levels, as well as tissue and urinary GAG contents, were measured. Results and conclusions: induced enzyme activity occurred both in the plasma and in the different tissues analyzed. A significant decrease in urinary undegraded GAG between the fourth and the sixth week of treatment was observed. Moreover, a biochemical reduction of GAG deposits was measured 8 weeks after treatment in the liver and kidney, on average 30 and 38{\%}, respectively, while in the spleen GAG levels were almost normalized. Finally, the therapeutic effect was confirmed by histolochemical examination of the same tissues. Such effects were obtained following implantation of about 1.5 × 106 recombinant cells/animal. Taken together, these results represent a clear evidence of the therapeutic efficacy of this strategy in the MPS II mouse model, and encourage further evaluation of this approach for potential treatment of human beings.",
keywords = "Gene therapy, Hunter syndrome, Lysosomal enzymes, Microcapsules, MPS II mouse model, Somatic cell therapy",
author = "Adelaide Friso and Rosella Tomanin and Sabrina Alba and Nicoletta Gasparotto and Puicher, {Elisabetta Piller} and Mariella Fusco and Gonzalo Hortelano and Joseph Muenzer and Oriano Marin and Franco Zacchello and Maurizio Scarpa",
year = "2005",
month = "11",
doi = "10.1002/jgm.790",
language = "English",
volume = "7",
pages = "1482--1491",
journal = "Journal of Gene Medicine",
issn = "1099-498X",
publisher = "John Wiley and Sons Ltd",
number = "11",

}

TY - JOUR

T1 - Reduction of GAG storage in MPS II mouse model following implantation on encapsulated recombinant myoblasts

AU - Friso, Adelaide

AU - Tomanin, Rosella

AU - Alba, Sabrina

AU - Gasparotto, Nicoletta

AU - Puicher, Elisabetta Piller

AU - Fusco, Mariella

AU - Hortelano, Gonzalo

AU - Muenzer, Joseph

AU - Marin, Oriano

AU - Zacchello, Franco

AU - Scarpa, Maurizio

PY - 2005/11

Y1 - 2005/11

N2 - Background: Hunter syndrome, mucopolysaccharidosis type II (MPS II), is a X-linked inherited disorder caused by the deficiency of the enzyme iduronate-2-sulfatase (IDS), involved in the lysosomal catabolism of the glycosaminoglycans (GAG) dermatan and heparan sulfate. Such a deficiency leads to the intracellular accumulation of undegraded GAG and eventually to a progressive severe clinical pattern. Many attempts have been made in the last two to three decades to identify possible therapeutic strategies for the disorder, including gene therapy and somatic cell therapy. Methods: In this study we evaluated the intraperitoneal implantation of allogeneic myoblasts over-expressing IDS, enclosed in alginate microcapsules, in the MPS II mouse model. Animals were monitored for 8 weeks post-implantation, during which plasma and tissue IDS levels, as well as tissue and urinary GAG contents, were measured. Results and conclusions: induced enzyme activity occurred both in the plasma and in the different tissues analyzed. A significant decrease in urinary undegraded GAG between the fourth and the sixth week of treatment was observed. Moreover, a biochemical reduction of GAG deposits was measured 8 weeks after treatment in the liver and kidney, on average 30 and 38%, respectively, while in the spleen GAG levels were almost normalized. Finally, the therapeutic effect was confirmed by histolochemical examination of the same tissues. Such effects were obtained following implantation of about 1.5 × 106 recombinant cells/animal. Taken together, these results represent a clear evidence of the therapeutic efficacy of this strategy in the MPS II mouse model, and encourage further evaluation of this approach for potential treatment of human beings.

AB - Background: Hunter syndrome, mucopolysaccharidosis type II (MPS II), is a X-linked inherited disorder caused by the deficiency of the enzyme iduronate-2-sulfatase (IDS), involved in the lysosomal catabolism of the glycosaminoglycans (GAG) dermatan and heparan sulfate. Such a deficiency leads to the intracellular accumulation of undegraded GAG and eventually to a progressive severe clinical pattern. Many attempts have been made in the last two to three decades to identify possible therapeutic strategies for the disorder, including gene therapy and somatic cell therapy. Methods: In this study we evaluated the intraperitoneal implantation of allogeneic myoblasts over-expressing IDS, enclosed in alginate microcapsules, in the MPS II mouse model. Animals were monitored for 8 weeks post-implantation, during which plasma and tissue IDS levels, as well as tissue and urinary GAG contents, were measured. Results and conclusions: induced enzyme activity occurred both in the plasma and in the different tissues analyzed. A significant decrease in urinary undegraded GAG between the fourth and the sixth week of treatment was observed. Moreover, a biochemical reduction of GAG deposits was measured 8 weeks after treatment in the liver and kidney, on average 30 and 38%, respectively, while in the spleen GAG levels were almost normalized. Finally, the therapeutic effect was confirmed by histolochemical examination of the same tissues. Such effects were obtained following implantation of about 1.5 × 106 recombinant cells/animal. Taken together, these results represent a clear evidence of the therapeutic efficacy of this strategy in the MPS II mouse model, and encourage further evaluation of this approach for potential treatment of human beings.

KW - Gene therapy

KW - Hunter syndrome

KW - Lysosomal enzymes

KW - Microcapsules

KW - MPS II mouse model

KW - Somatic cell therapy

UR - http://www.scopus.com/inward/record.url?scp=27944473627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27944473627&partnerID=8YFLogxK

U2 - 10.1002/jgm.790

DO - 10.1002/jgm.790

M3 - Article

VL - 7

SP - 1482

EP - 1491

JO - Journal of Gene Medicine

JF - Journal of Gene Medicine

SN - 1099-498X

IS - 11

ER -